Core Viewpoint - Kaisheng Technology (600552.SH) clarified on its investor interaction platform that the company primarily produces display materials and application materials, and does not have any business or technology related to T-glass micro glass fiber [1] Company Summary - The company focuses on the production of display materials and application materials [1] - There is no involvement in T-glass micro glass fiber business or technology [1]

Core Viewpoint - Fuyao Glass (600660.SH) has made substantial progress in integrating solar technology with automotive applications, specifically through the development of solar sunroof glass that converts solar energy into electrical power for vehicle accessories [1] Group 1 - The company has developed solar sunroof glass that incorporates solar cell components within the glass interlayer [1] - This innovation allows the conversion of solar energy into electrical power, providing auxiliary power for in-vehicle electronics [1] - The company has achieved mass production capability for the solar sunroof glass [1]

格隆汇2月12日丨中国中冶(01618.HK)公告，公司2026年1月新签合同额人民币736.5亿元，其中新签海 外合同额人民币32.1亿元。 ...

Core Viewpoint - The company, Autohome Inc. (02518.HK), will hold a board meeting on March 5, 2026, to approve its unaudited financial results for the three months and the full year ending December 31, 2025 [1] Group 1 - The board meeting is scheduled for Thursday, March 5, 2026, Hong Kong time [1] - The meeting will include discussions on the company's financial performance for the three months and the full year ending December 31, 2025 [1]

Group 1 - The company Xuanwu Cloud (02392.HK) announced a share buyback on February 12, 2023, spending HKD 33,000 to repurchase 22,500 shares [1]

Core Viewpoint - Kangzheng Pharmaceutical (00867.HK) has signed an exclusive distribution agreement for Lidoderm® with Teikoku PharmaUSA, Inc., granting the company exclusive rights in the target region of mainland China for a period of ten years, with potential for renewal [1] Group 1: Agreement Details - The agreement is established between Kangzheng Pharmaceutical and Teikoku PharmaUSA, Inc., a subsidiary of Teikoku Seiyaku Co., Ltd [1] - The product involved in the agreement is Lidoderm® (lidocaine transdermal system) [1] - The cooperation period begins from the first commercial sale of the product in the target region and lasts for ten years, with options for renewal as per the agreement [1] Group 2: Responsibilities - Kangzheng Pharmaceutical will hold exclusive distribution rights in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - Teikoku PharmaUSA, Inc. is responsible for the production and supply of the product [1]

公司于2026年2月12日召开了第二届董事会第九次会议，审议通过了《关于补选公司第二届董事会非独 立董事的议案》，提名FANGJANE JING AN(方静安)女士为公司第二届董事会非独立董事候选人，其任 职期限自股东会审议通过之日起至第二届董事会任期届满为止。本次补选公司非独立董事事项需提交股 东会审议。 格隆汇2月12日丨小方制药(603207.SH)公布，公司董事会于2026年2月12日收到公司董事FANG JACKSON JIA CHEN(方家辰)先生的书面辞职报告。FANG JACKSON JIA CHEN(方家辰)先生因工作原 因，向公司董事会申请辞去公司董事职务，该辞职报告自送达董事会之日起生效。 ...

格隆汇2月12日丨南威软件(603636.SH)公布，公司于2026年2月12日收到原持股5%以上股东启重始源发 来的《简式权益变动报告书（启重始源）》及《关于权益变动触及5%刻度的告知函》，启重始源于 2026年2月11日-2026年2月12日，通过集中竞价方式减持公司股份493.4万股。本次权益变动后，启重始 源持有公司股份数量由33,952,000股减少至29,018,000股，持股比例由5.850157%下降至4.999995%。 ...

格隆汇2月12日丨瑞普生物(300119.SZ)公布，为推进公司核心战略落地，拓展重点领域业务边界与行业 影响力，充分借助专业机构的资本与资源优势，瑞普生物股份有限公司于2026年2月12日与海通并购 （上海）私募基金管理有限公司（简称"海通并购资本"）、海通开元投资有限公司（简称"海通开元投 资"）、高邮市产业引导基金（有限合伙）（简称"高邮产业引导基金"）及关联方天津瑞晟私募基金管 理有限公司（简称"瑞晟私募"）签署《江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）之合伙协 议》，拟共同出资设立江苏国泰海通瑞普并购产业基金合伙企业（有限合伙）（暂定名，以市场监督管 理机关核准的名称为准，简称"合伙企业"）。该合伙企业将聚焦动物保健、合成生物、宠物、生物医药 等重点领域开展产业投资。合伙企业认缴出资总额为人民币10亿元，其中，公司作为有限合伙人以自有 资金及自筹资金出资人民币2.95亿元，占合伙企业认缴出资总额的29.50%。 ...

Core Viewpoint - Xiamen Bank (601187.SH) announced the election of Mr. Wang Jianping as the employee director of the ninth board of directors during the 14th meeting of the sixth employee representative assembly and the 13th meeting of the trade union members assembly, scheduled for February 12, 2026 [1] Summary by Categories - **Board Election** - Mr. Wang Jianping has been elected as the employee director of the ninth board of directors [1] - **Meeting Details** - The meeting will take place on February 12, 2026, and will include both the employee representative assembly and the trade union members assembly [1] - **Regulatory Approval** - The appointment of Mr. Wang Jianping will take effect upon approval from regulatory authorities, with the term lasting until the ninth board of directors concludes its term [1]